Skip to main content

Targeting the tumour microenvironment to improve pancreatic cancer prognosis

Objective

Pancreatic cancer is one of the most lethal human cancers with a five-year survival rate of less than 5%. Late presentation and a high level of resistance to chemotherapeutic drugs are among the major reasons for this dismal prognosis. The presence of the highest degree of desmoplasia among all solid tumours and the fact that chronic inflammatory pancreatic disease is associated with an increased risk for pancreatic cancer indicate, that the tumour microenvironment is of particular importance for carcinogenesis in the pancreas. The long-term objective of this proposal is to increase survival of pancreatic cancer patients by exploring the contribution of the tumour microenvironment to the failure of presently available oncological treatments. For this purpose the clinical observation will be reverse-translated into innovative in-vitro and mouse models closely mimicking the human disease. This will allow a profound study of the mechanistic basis of treatment failure by deciphering the complex network between components of the microenvironment and cancer cells leading to increased resistance to chemotherapy and infiltrative growth along adjacent lymphatic and neural structures as well as metastatic spread. Identification of cancer (stem) cell-autonomous as well as stromal-derived mediators of invasion and chemoresistance will lead to novel drug targets to overcome the current therapeutic dilemma. The consortium has been specifically designed to include all required levels of expertise: 1) surgical and medical oncology groups conducting the largest clinical trials for pancreatic cancer in Europe, 2) expert pancreatic pathologists, 3) basic scientists focused on the study of carcinogenesis and tumour microenvironment interactions in the pancreas, 4) molecular oncology groups that have developed genetically engineered mouse models faithfully recapitulating human pancreatic cancer, as well as 5) pharmaceutical industry specialised on drug development.

Field of science

  • /medical and health sciences/clinical medicine/cancer/pancreatic cancer

Call for proposal

FP7-HEALTH-2010-two-stage
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

PHILIPPS UNIVERSITAET MARBURG
Address
Biegenstrasse 10
35037 Marburg
Germany
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 626 777
Administrative Contact
Sandra Basenau (Ms.)

Participants (16)

THE UNIVERSITY OF LIVERPOOL
United Kingdom
EU contribution
€ 248 800
Address
Brownlow Hill 765 Foundation Building
L69 7ZX Liverpool
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Veronica Shaw (Ms.)
FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III
Spain
EU contribution
€ 550 000
Address
Calle Melchor Fernandez Almagro 3
28029 Madrid
Activity type
Research Organisations
Administrative Contact
Laura Bertolini (Ms.)
UNIVERSITA DEGLI STUDI DI VERONA
Italy
EU contribution
€ 145 000
Address
Via Dell Artigliere 8
37129 Verona
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Enrico Cazzaroli (Dr.)
UNIVERSITAET GREIFSWALD
Germany
EU contribution
€ 270 000
Address
Domstrasse 11
17489 Greifswald
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Andrea Völker (Dr.)
KAROLINSKA INSTITUTET
Sweden
EU contribution
€ 207 560
Address
Nobels Vag 5
17177 Stockholm
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Rolf Trana (Mr.)
Axcentua Pharmaceuticals AB

Participation ended

Sweden
EU contribution
€ 72 440
Address
Alfred Nobels Alle 10
14152 Huddinge
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Michael-Robin Witt (Dr.)
KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN
Germany
EU contribution
€ 131 400
Address
Ismaninger Strasse 22
81675 Muenchen
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Beate Schaulin (Ms.)
Bayer Pharma AG
Germany
EU contribution
€ 76 462
Address
Muellerstrasse 178
13353 Berlin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Delia Nölte (Mrs.)
CANCER RESEARCH UK LBG

Participation ended

United Kingdom
EU contribution
€ 144 365
Address
St John Street 407 Angel Building
EC1V 4AD London
Activity type
Research Organisations
Administrative Contact
Emma Ryley (Dr.)
LAB 21 LIMITED

Participation ended

United Kingdom
EU contribution
€ 20 758
Address
Cambridge Science Park 184
CB4 0GA Cambridge
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Anthony Cooke (Dr.)
FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR
Italy
EU contribution
€ 60 000
Address
Via Olgettina 60
20132 Milano
Activity type
Research Organisations
Administrative Contact
Mario Valsecchi
UNIVERSITA DEGLI STUDI DI TORINO
Italy
EU contribution
€ 60 000
Address
Via Giuseppe Verdi 8
10124 Torino
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Antonio Baldassarre (Mr.)
NATIMAB THERAPEUTICS SRL
Italy
EU contribution
€ 45 000
Address
Via Ribes 5
10010 Colleretto Giacosa Torino
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Gianni Garotta (Prof.)
Concentris Research Management GmbH
Germany
EU contribution
€ 202 838
Address
Ludwigstr. 4
D-82256 Fürstenfeldbruck
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Ameli Schwalber (Ms.)
TECHNISCHE UNIVERSITAET MUENCHEN
Germany
EU contribution
€ 138 600
Address
Arcisstrasse 21
80333 Muenchen
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Katrin Hörmann (Ms.)
FONDAZIONE CENTRO SAN RAFFAELE
Italy
Address
Via Olgettina 60
20132 Milano
Activity type
Research Organisations
Administrative Contact
Maria Rosa Pedrazzi (Dr.)